This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
For BeneFIX® (nonacog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
BeneFIX® offers frequent, flexible dosing so you and your patients are covered for everyday life. Dose and dose intervals should be based on patients' bleeding profile.1
Dosing with BeneFIX
BeneFIX® powder and solvent for solution for injection is available in 250 IU, 500 IU, 1000 IU, 2000 IU.2
For a recovery of 0.8 IU/dL, the required dose is determined using the following formula1:
The calculation of the required dose of BeneFIX can be based on the finding that one unit of factor IX activity per Kg body weight is expected to increase the circulating level of factor IX, an average of 0.8 IU/dL (range from 0.4 to 1.4 IU/dL) in patients ≥ 12 years.1
For further information consult BeneFIX Summary of Product Characteristics.
This image shows the R2 device colour-coded packaging. Each colour corresponds to a different vial dose, making it easier to identify.
Find out more about choosing BeneFIX: why and the commitment Pfizer has towards Haemophilia care.
Access data on the clinical efficacy & safety of BeneFIX® for prophylaxis, on-demand treatment, and surgery.
Contact us for more information on BeneFIX® and download our FAQ for supply and stock related queries.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024